This journal article characterizes the effects of Cyclerion’s systemic sGC stimulator, praliciguat, in models of nonalcoholic steatohepatitis (NASH), identifying key target cells and downstream signaling pathways responsible for the observed pharmacology. These data support the potential utility of sGC stimulation as a promising mechanism in the treatment of NASH and fibrotic liver diseases.